Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Dow
Boehringer Ingelheim
Argus Health
Cantor Fitzgerald
Merck
Colorcon
Harvard Business School
McKesson

Generated: December 14, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,376,515

« Back to Dashboard

Which drugs does patent 6,376,515 protect, and when does it expire?

Patent 6,376,515 protects BEVYXXA and is included in one NDA.

This patent has fifty-seven patent family members in twenty-two countries.

Summary for Patent: 6,376,515
Title: Benzamides and related inhibitors of factor Xa
Abstract:Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Inventor(s): Zhu; Bing-Yan (Belmont, CA), Zhang; Penglie (Foster City, CA), Wang; Lingyan (Chatham, NJ), Huang; Wenrong (Cupertino, CA), Goldman; Erick A. (San Francisco, CA), Li; Wenhao (South San Francisco, CA), Zuckett; Jingmei (Glendale, AZ), Song; Yonghong (Foster City, CA), Scarborough; Robert M. (Half Moon Bay, CA)
Assignee: COR Therapeutics, Inc. (South San Francisco, CA)
Application Number:09/794,225
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Device;

Drugs Protected by US Patent 6,376,515

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS ➤ Sign Up
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF PULMONARY EMBOLISM ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Medtronic
Accenture
McKesson
Daiichi Sankyo
Federal Trade Commission
UBS
Covington
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.